KURA vs. MORF, RCUS, AKRO, DAWN, EWTX, ANIP, ARDX, GYRE, ZLAB, and DVAX
Should you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Morphic (MORF), Arcus Biosciences (RCUS), Akero Therapeutics (AKRO), Day One Biopharmaceuticals (DAWN), Edgewise Therapeutics (EWTX), ANI Pharmaceuticals (ANIP), Ardelyx (ARDX), Gyre Therapeutics (GYRE), Zai Lab (ZLAB), and Dynavax Technologies (DVAX). These companies are all part of the "pharmaceutical preparations" industry.
Kura Oncology (NASDAQ:KURA) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, community ranking, profitability, valuation, institutional ownership and risk.
Kura Oncology currently has a consensus price target of $28.28, suggesting a potential upside of 39.92%. Morphic has a consensus price target of $51.50, suggesting a potential upside of 84.59%. Given Morphic's higher probable upside, analysts plainly believe Morphic is more favorable than Kura Oncology.
Kura Oncology has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Morphic has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.
94.3% of Morphic shares are held by institutional investors. 5.5% of Kura Oncology shares are held by insiders. Comparatively, 28.1% of Morphic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Morphic has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Morphic, indicating that it is currently the more affordable of the two stocks.
Kura Oncology received 320 more outperform votes than Morphic when rated by MarketBeat users. Likewise, 68.74% of users gave Kura Oncology an outperform vote while only 59.54% of users gave Morphic an outperform vote.
Morphic's return on equity of -22.93% beat Kura Oncology's return on equity.
In the previous week, Morphic had 3 more articles in the media than Kura Oncology. MarketBeat recorded 7 mentions for Morphic and 4 mentions for Kura Oncology. Morphic's average media sentiment score of 1.07 beat Kura Oncology's score of 0.59 indicating that Morphic is being referred to more favorably in the news media.
Summary
Morphic beats Kura Oncology on 11 of the 16 factors compared between the two stocks.
Get Kura Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Kura Oncology Competitors List
Related Companies and Tools